Learning sharks-Share Market Institute

To know more about the Stock Market Courses Call or chat Rajouri Garden 8595071711 or Noida 8920210950

zim laboratories stock/share price – learning sharks

Multibagger pharma stock announces 2:1 bonus shares, and net profit increases 182% in Q2

Learning sharks Stock market Institute

Zim Laboratories Ltd. is a small-cap company that operates in the pharmaceutical sector with a market valuation of $509.10 Cr. The company also provides finished formulations (FF) and pre-formulation intermediates (PFI) for a number of important therapeutic categories in addition to developing, producing, and delivering unusual generic pharmaceuticals in oral solid doses. A 2:1 bonus share issuance was announced along with the company’s Q2 earnings.

Zim Laboratories’ bonus share information according to data from stock exchanges


3,24,83,876 equity shares worth Rs. 10 each make up the total number of securities proposed for issuance or the approximate total amount for which the securities will be issued.

Whether bonus shares are issued from share premium accounts or free reserves made from profits, the bonus shares will be issued from the securities premium accounts available as of March 31, 2022.

Bonus Ratio: 2:1, or 2 (two) equity shares worth Rs. 10 each for every 1 (one) equity share worth Rs. 10 each that has been fully paid up. Paid-up Pre-Bonus Issue 16,24,19,380 rupees worth of equity shares are divided into 1,62,41,938 shares, each worth 10 rupees. Paid-up Post-Bonus Issue 4,87,25,814 equity shares worth Rs. 10 each make up the share capital of Rs. 48,72,58,140.

Required Free Reserves and/or Share Premium for the Bonus Issue: Rs. 32,48,38,760 would be capitalized from the Securities Premium Account for the issuance of Bonus Shares.

In Q2FY23, the company reported total expenses of 92.54 crores, up from 73.68 crores in Q2FY22, a YoY increase of 25.59%. In Q2FY23, the company reported a profit before tax (PBT) of $8.15 million, up from Q2FY22’s PBT of $2.92 million, a YoY gain of 179.10 percent. In comparison to the net profit of 2 Cr reported in Q2FY22, the company reported a net profit of 5.65 Cr in Q2FY23, an increase of 182.50% YoY. In Q2FY23, the EPS increased to $3.49 per share from $1.24 in Q2FY22 and $3.47 in Q1FY23.

The date that such bonus shares are anticipated to be credited or sent: The Bonus shares will be credited/delivered within two months of the date of the Board approval, or on or before January 11, 2023, subject to obtaining shareholder approval, Statutory/Regulatory approvals, and other approvals, as may be necessary.

Click here to see more fundamentals on the screener app. To learn more about the courses, click here

Separately, the company reported net sales of 99.26 crores in Q2FY23 compared to 75.72 crores in Q2FY22, an increase of 31.08% year over year. In the three months that ended in September 2022, the company reported a net income of $100.70 Cr, up from the 76.61 Cr reported in the same period the previous year. This represents a YoY growth of 31.44%.

On a consolidated basis, the company reported net sales of 99.40 crores in the second quarter of FY23, up from 77.47 crores in the same quarter of FY22, or a YoY increase of 28.30%. In comparison to the 78.34 Cr reported in Q2FY22, the company reported a total income of $100.82 Cr, representing a YoY growth of 286.90%. In Q2FY23, the company reported total expenses of 92.86 crores, up from the 74.14 crores reported in Q2FY22, a YoY gain of 25.24%. In Q2FY23, the company reported a PBT of $7.95 million, up from the $4.20 million reported in Q2FY22, a YoY increase of 89.28%.

Zim Laboratories Ltd.’s shares ended trading on Friday at 313.50 per share, up 0.064% from the previous close of 313.30. Over the last five years, the stock has generated a multi-bagger return of 146.40%, and over the last three years, a multi-bagger return of 282.49%. Over the past year, the stock has produced a multi-bagger return of 150.90%, and YTD in 2022, it has done so with a multi-bagger return of 163.56%.